Autopsy report · NCT06860672

Clinical Trial of the Dual Vector Base Editor for the Treatment of the CHD3-R1025W Mutation

“The single participant died on 31 March 2025 from thrombotic microangiopathy, a serious adverse event assessed as definitely related to the study drug. Planned follow-up was not completed, and the study was terminated.”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 1 month before it stopped.
• 1 participant enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Early Phase 1

Sponsor

Yongguo Yu

Sponsor type

University, hospital or other

Conditions

Developmental Delay Disorder; Intellectual Disability; Rare Diseases

Interventions

Dual vector DNA base editor

Participants

1

Sites

1

Countries

China

Trials that died the same way

• A Study Of Safety, Tolerability And Effectiveness Of Recifercept In Children With Achondroplasia
  “The study was terminated due to lack of efficacy at any of the tested doses on 18th November 2022. The decision to terminate the study is not related to a safety concern.” (58% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.